Literature DB >> 12803351

Assessing residents' prescribing behavior in renal impairment.

L Salomon1, S Levu, G Deray, V Launay-Vacher, G Brücker, P Ravaud.   

Abstract

OBJECTIVE: Although fitting orders to renal function avoids overdosage and therefore iatrogenic risk, dosage adjustment is rarely made. The objective of this study was to assess residents' prescribing behavior in renal impairment, through a standardized simulated clinical setting.
METHOD: This criterion-referenced study was carried out in a French teaching hospital. The hospital had 118 residents; 71 of them were asked to complete a questionnaire including four vignettes, simulating drug prescription in four 'patients' with various degrees of renal impairment (16 orders). The patients had an order of gentamicin sulfate, diclofenac sodium, and amlodipine bensylate. For each drug, the resident could maintain the order, discontinue the order, or change the dosage. A fourth drug, enalapril maleate, was to be started, with three possible dosages and the possibility of not prescribing it. The reference chosen for assessment was the Vidal dictionary, which corresponds to the Physician's Desk Reference and is the French reference for prescription.
RESULTS: All the residents approached for the survey accepted the offer to complete the questionnaire. Among the 16 simulated orders, the median number of appropriate orders per resident was nine. Considering the renal function of their patients, 62% of residents wrote an inappropriate order for gentamicin, 42% wrote an inappropriate order for didofenac, and 52% wrote an inappropriate order for enalapril. Although no adjustment to renal function was required, 28% of the residents decreased the dosage of amlodipine and ordered an underdose.
CONCLUSION: Considering the iatrogenic risk related to the lack of dosage adjustment, attention should be drawn to increasing residents' awareness of dosage adjustment in renal impairment and to providing them with better information on patients' renal function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12803351     DOI: 10.1093/intqhc/mzg034

Source DB:  PubMed          Journal:  Int J Qual Health Care        ISSN: 1353-4505            Impact factor:   2.038


  7 in total

1.  Assessing general practitioners' prescribing behaviour in elderly patients with concealed renal failure.

Authors:  Annie Pierre Jonville-Béra; Lucie Paroux; Elisabeth Autret-Leca
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

2.  Impact of a clinical decision support system for drug dosage in patients with renal failure.

Authors:  Sophie Desmedt; Anne Spinewine; Michel Jadoul; Séverine Henrard; Dominique Wouters; Olivia Dalleur
Journal:  Int J Clin Pharm       Date:  2018-05-21

3.  Avoidability of adverse drug reactions spontaneously reported to a French regional drug monitoring centre.

Authors:  Annie Pierre Jonville-Béra; Hassan Saissi; Lamiae Bensouda-Grimaldi; Frederique Beau-Salinas; Haware Cissoko; Bruno Giraudeau; Elisabeth Autret-Leca
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

4.  Appropriateness of drug dose and frequency in patients with renal dysfunction in a tertiary care hospital: A cross-sectional study.

Authors:  Arpit Prajapati; Barna Ganguly
Journal:  J Pharm Bioallied Sci       Date:  2013-04

5.  The rate of antibiotic dosage adjustment in renal dysfunction.

Authors:  Fanak Fahimi; Sepideh Emami; Farin Rashid Farokhi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

6.  Impact of therapeutic and high doses of florfenicol on kidney and liver functional indicators in goat.

Authors:  Jan Muhammad Shah; Toufique Ahmed Qureshi; Tahmina Shah; Qurban Ali Shah; Muhammad Asif Arain; Zohaib Ahmed Bhutto; Muhammad Saeed; Farman Ali Siyal
Journal:  Vet World       Date:  2016-10-24

7.  Drug dosage adjustment in hospitalized patients with renal impairment at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia.

Authors:  Henok Getachew; Yewondwossen Tadesse; Workineh Shibeshi
Journal:  BMC Nephrol       Date:  2015-10-07       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.